Research
Hormonal
The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.
Practitioners should be aware of the gastrointestinal side effects associated with orforglipron, particularly during dose escalation.
StrongSupportsmedium confidence
The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation.
Why this rating
Based on the phase 2 randomized, double-blind trial design.
Source
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton et al. · New England Journal of Medicine · 2023
rct · n=272Cited 412×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →